FDA Approves First Biosimilar for Non-Hodgkin's Lymphoma

14:35 EST 28 Nov 2018 | Pharmacy Times

Rituximab-abbs (Truxima, Celltrion) is the fifteenth biosimilar approved by the FDA and the sixth biosimilar approved in 2018, thus far.

Original Article: FDA Approves First Biosimilar for Non-Hodgkin's Lymphoma


More From BioPortfolio on "FDA Approves First Biosimilar for Non-Hodgkin's Lymphoma"

Quick Search

Relevant Topics

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...